Pamidronic Acid

Pamidronate is an aminobisphosphonate that, like other bisphosphonates, inhibits bone resorption. It is used to treat Paget's disease, severe hypercalcemia, and osteolytic bone lesions associated with malignancy. It is administered by slow intravenous infusion every day or every 3 to 4 weeks depending on the disease.

Pamidronate is excreted in breast milk in undetectable concentration. ^{(Siminoski 2000)}

Most bisphosphonates are acidic compounds that achieve low plasma concentration. Both features make it unlikely excretion into the milk in clinically significant amount. Intestinal absorption of bisphosphonates is very low even during fasting and is considered negligible in the presence of milk due to formation with the calcium of non absorbable compounds.

No problems have been observed in infants of mothers treated with pamidronate ^{(Mastaglia 2010, Shenker 2010, Chan 2006, Siminoski 2000)},except some cases of mild and asymptomatic hypocalcemia in infants whose mothers had been already treated before and / or during pregnancy ^{(Hassen 2010, Munns 2004)}, so some authors suggest regular monitoring of serum calcium. ^{(Green 2014, Stathopoulos 2011)}

Most osteoporosis treatments are compatible with breastfeeding.

See below the information of these related products:

• Maternal Cancer (Unsafe. Moderate/severe adverse effects. Compatible under certain circumstances. Follow-up recommended. Use safer alternative or discontinue breastfeeding from 5 to 7 T ½ . Read Commentary.)
• Maternal osteoporosis (Safe substance and/or breastfeeding is the best option.)